|Bid||326.00 x 800|
|Ask||326.49 x 2200|
|Day's range||317.18 - 335.75|
|52-week range||65.49 - 497.49|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||38.58|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.
Yahoo Finance's Anjalee Khemlani discusses the latest CDC recommendations, including mixing and matching vaccine boosters.
Shares of Moderna (NASDAQ: MRNA) were falling 5.4% as of 11 a.m. EDT on Friday. The decline came after Deutsche Bank (NYSE: DB) initiated coverage on the stock with a sell rating. The investment firm set a price target for Moderna of $250, roughly 26% below the closing price on Thursday.